SPEECH as Biomarker for Emotion, Movement and cOgnition in Parkinson's Disease

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age30-75
SponsorInsel Gruppe AG, University Hospital Bern

About this trial

With this study, the investigators want to investigate whether computerized speech analysis can be used to reliably and objectively detect motor, emotional, and cognitive fluctuations in Parkinson's disease patients.

Eligibility criteria

Qualifiers

Written informed consent

Idiopathic PD according to the Movement Disorders Society Criteria;

Age of participants > 30 and ≤ 75 years;

Treatment with or without bilateral deep brain stimulation in the subthalamic nucleus;

Disqualifiers

Dysarthria caused in addition by a condition other than PD (e.g. stroke, myasthenia);

Clinical diagnosis of aphasia;

Brain disease other than Parkinson's disease (e.g. atypical Parkinsonism, Alzheimer's disease, vascular dementia, multiple sclerosis, stroke, traumatic brain injury, epilepsy, etc.).

Cognitive impairment (Montreal Cognitive Assessment (MoCa) < 24/30 points);

Trial design

Treatments tested in this trial

  • Dopaminergic OFF drug state
  • DBS OFF state
  • Dopaminergic ON drug state
  • DBS ON state

Treatment groups

80 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Insel Gruppe AG, University Hospital Bern

Lead sponsor

Czech Technical University in Prague

Collaborator